Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review

Afatinib, the world’s first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a second-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It can be used as a fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yingying, Fang, Xiaoxu, Xiang, Yan, Fang, Tingwen, Liu, Jingwen, Lu, Kaihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297373/
https://www.ncbi.nlm.nih.gov/pubmed/37366888
http://dx.doi.org/10.3390/curroncol30060405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297373/
https://www.ncbi.nlm.nih.gov/pubmed/37366888
http://dx.doi.org/10.3390/curroncol30060405

Ejemplares similares